Zepteon

 

glycan

Austin W. Boesch, CEO, co-inventor and co-founder of Zepteon, Inc., has 7 years of industrial R&D experience in the biopharmaceutical field. While working at Millipore he was integral to the development of a commercially available virus retention filter. While at Pfizer he performed purification process development for molecules in the clinical pipeline and commercially launched molecules. This experience gave him extensive expertise in the field of chromatography. Mr. Boesch is an Innovation PhD fellow at the Thayer School of Engineering at Dartmouth College and has training in law, technology, entrepreneurship, financial accounting and corporate finance from the Tuck School of Business at Dartmouth College. His research at Dartmouth has included the molecular biology techniques and cellular manipulations to produce and purify recombinant human receptors. He has more than 12 publications and patents.

glycan

Dr Glen R. Bolton, COO, co-inventor and co-founder, has a PhD in chemical engineering from MIT and also received training in marketing, finance, accounting, economics, leadership and organizational behavior while at MIT. He has more than 15 years of protein purification and project management experience in the pharmaceutical industry. He helped lead the commercialization of two protein purification products during his tenure at Millipore. He developed and validated the purification processes for multiple early and late stage clinical antibodies while at Pfizer, Biogen, and Amgen. In addition, he has developed the purification processes for biosimilar antibodies with targeted glycosylation profiles. He taught the Protein Purification and Cell and Microbe Cultivation courses at Tufts. He has more than 25 publications and patents, has served on two Parenteral Drug Association task forces, and was the industrial chair of the BIOT division of the 2014 American Chemical Society Conference.

Tom Ransohoff, Strategic Advisor, has over twenty years in the biopharmaceutical industry, in areas ranging from product and technology development to cGMP manufacturing. In addition to his previous leadership roles at Tarpon Biosystems and at BioFlash Partners LLC wher he served as CEO, Mr. Ransohoff is a Senior Consultant with Bioprocess Technology Consultants, a leading biopharmaceutical CMC consulting firm. Mr. Ransohoff's previous experience includes senior positions with business unit and operational responsibility at TranXenoGen, Dyax, Repligen, and Xoma. Mr. Ransohoff has a Bachelor's degree from MIT and a Master's degree from UC-Berkeley, both in Chemical Engineering.

Marc Silver, Strategic Advisor, is a senior executive with broad ranging business management skills gained from over 25 years’ experience in the biopharmaceutical industry. He has developed a range of funded initiatives including new company business plans and new company programs and has a deep track record of transaction negotiation including “out-licensing”, “in-licensing”, partnering and financing. Marc was the VP of business development at BioWa from 2009-2012 and has an MBA from MIT.

Ronald Sia, Strategic Advisor, has served as an attorney for seven years at Procter & Gamble and Gillette. He has handled supporting a global $1 billion business and provided business guidance on innovation and commercial strategies across new products and base business initiatives. He has served as the lead attorney on multiple domestic and foreign disputes including advertising challenges and patent infringement cases. He has received a JD from UNH and a BS in chemical engineering from Tufts University.